Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH;
OTCQX:EMHTF) today announced that its joint venture partner’s,
(Emerald Health Bioceuticals or “EHB”), Endo Bliss, won Taste For
Life’s 2019 Essentials Supplement Award, which recognizes the most
outstanding natural supplements in health and wellness in the U.S.
Emerald will launch the Endo product line in Canada in 2019 through
its joint venture, Emerald Health Naturals (“EHN”), which secured
Canadian distribution rights for this product line that was
developed to support the body’s endocannabinoid system (“ECS”), but
which does not contain cannabis.
Endo Bliss is part of the Endo product line of
novel nutritional supplements created to support the human ECS.
Formulated to promote positive outlook and mood, Endo Bliss
features Emerald’s proprietary PhytoCann® Complex, an herbal and
botanical complex completely free of cannabis or its derivatives.
Saffron extract, which has been proven to improve mood and outlook,
is also included in the formula to further bolster its
efficacy.
“Endo Bliss’ recognition as a top natural
supplement to support endocannabinoid health by Taste for Life
in the U.S. is a notable accolade,” said Gaetano Morello, ND, CEO
of Emerald Health Naturals. “The Endo product line offers people
who use natural health products a completely new and unique
category of nutritional supplement. To receive this award, at a
time when more US retailers are showing interest in putting Endo on
their shelves, is added confirmation to us that Endo is fulfilling
an unmet need in the marketplace for non-cannabis products that
support the endocannabinoid system.
“We aim to launch the Endo line this year via an
extensive nationwide retail network of Canadian retailers that will
far exceed the current number of cannabis retail stores. We will
not only create a unique profit opportunity with this product line,
we will create significant incremental recognition for Emerald
cannabis products and an entrenched presence in natural health
food, pharmacy and other channels should non-psychoactive cannabis
products be permitted in these channels in the future.”
The endocannabinoid system is a biological
system critical in establishing and maintaining homeostasis in
every cell, tissue and organ in the body. EHB harnessed the power
of non-cannabis herbs and botanicals to offer a complete
nutritional line of supplements that supports the endocannabinoid
system to address consumers’ most common health concerns. In
addition to Endo Bliss, Emerald’s lineup includes Endo Sleep, Endo
Brain, Endo Calm and Endo Inflame for rejuvenating rest, enhanced
cognition, stress and anxiety support, and pain and inflammation
relief.
Over the last year, EHB has secured multiple
distribution and sales channels for the Endo product line in the
United States and internationally, ranging from small independent
natural health product retailers to nationwide grocery store chains
like Whole Foods Market, as well as Amazon.com. EHN has not
announced Canadian retailers.
About Taste For Life
Taste For Life aims to educate and motivate
consumers to make informed purchasing decisions. Utilizing research
and insights from industry experts, the magazine covers food and
special diets, vitamins, minerals, supplements, herbs, homeopathy,
natural food and beauty products, recipes and other products or
modalities for overall wellness.
About The Endo Product
Line*
Endo Brain - Naturally supports
mental acuity and cognition by nurturing and nourishing your
endocannabinoid system.
Endo Sleep - Enjoy restful and
rejuvenating sleep by naturally supporting your endocannabinoid
system, optimal health and vitality.
Endo Calm - Naturally addresses
your body’s response to stress and anxiety by supporting your
endocannabinoid system and optimal health and vitality.
Endo Bliss - Naturally supports
a positive outlook and resistance to daily pressures by nurturing
and nourishing your endocannabinoid system.
Endo Inflame - Naturally
promotes your body’s healthy response to pain and inflammation by
supporting your endocannabinoid system for optimal health and
vitality.
* The statements made herein have not been
evaluated by Health Canada or the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent
any disease.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is completing the conversion of its 1.1 million
square foot (25 acre) greenhouse for cannabis cultivation in the
Lower Mainland and its Verdélite operation in Québec is completing
the build out of its 88,000 square feet indoor cultivation
facility. Commercial production is expanding in both facilities.
Emerald secured over 500 acres of hemp harvest in 2018 and has
contracted for approximately 1000 acres in 2019 to 2022, with the
objective of extracting low-cost cannabidiol (CBD). Emerald’s team
is highly experienced in life sciences, product development,
large-scale agri-business, and marketing, and is focused on
developing proprietary, value-added cannabis products for medical
and adult-use customers. Emerald is part of the Emerald Health
group, which represents a broad array of companies focused on
developing pharmaceutical, botanical, and nutraceutical products
developed to provide wellness and medical benefits by interacting
with the human body’s endocannabinoid system.
Please visit http://www.emeraldhealth.ca for
more information or contact:
Rob Hill, Chief Financial Officer(800) 757 3536
Ext. #5
Investor Relations(800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include completion of the joint venture and obtaining exclusive
Canadian distribution rights; establishing a brand; launch of the
Endo line in 2019; sales of non-cannabis products; development of
sales channels; expansion of permitted sales of cannabis;
leveraging of distribution channels; development of new products;
the benefits and effects of certain products; production capacity
of various facilities; and receipt of hemp deliveries.
Actual results may vary from forward-looking
statements. We cannot guarantee that any forward-looking statement
will materialize, and readers are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking
statements involve risks and uncertainties related to, among other
things, failure to obtain necessary financing; failure to settle
final documentation; failure to obtain regulatory approvals;
results of production and sale activities; results of scientific
research; regulatory changes; changes in prices and costs of
inputs; demand for labour; demand for products; future distribution
agreements; failure of counterparties to perform contractual
obligations; as well as the risk factors described in the Company’s
annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024